Effect of patient adherence to antiretroviral therapy on the progression of cervical dysplasia among HIV-infected women

AIDS Reader

Volumn 18, Issue 7, 2008, Pages 382-385

  Bernal, Amparo ^a   Walters, Scott T ^b   Paulson, Rene M ^b   Mubasher, Mohamed ^c  

^a PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c TEXAS WOMAN'S UNIVERSITY   (United States)

Author keywords

Adherence; Antiretroviral therapy; Cancer; Cervical dysplasia; Clinical investigation; HIV AIDS; Women's issues

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; COLPOSCOPY; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; REMISSION; UTERINE CERVIX DYSPLASIA; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; UTERINE CERVICAL DYSPLASIA;

EID: 47249099053     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
2. Sun XW, Ellerbrock TV, Lungu O, et al. Human papillomavirus infection in human immunodeficiency virus-seropositive women. Obstet Gynecol. 1995;85(5, pt 1):680-686.
3. Garland SM. Human papillomavirus update with a particular focus on cervical disease. Pathology. 2002;34:213-224.
4. Bosch XF, de Sanjose S. Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;31:3-13.
5. Herrington CS. Do HPV-negative cervical carcinomas exist? - revisited. J Pathol. 1999;189:1-3.
6. Williamson AL, Marais D, Passmore JA, Rybicki E. Human papillomavirus (HPV) infection in Southern Africa: prevalence, immunity, and vaccine prospects. IUBMB Life. 2002;53:253-258.
7. Marais DJ, Vardas E, Ramjee G, et al. The impact of human immunodeficiency virus type 1 status on human papillomavirus (HPV) antibodies in serum and cervical secretions. J Infect Dis. 2000;182:1239-1242.
8. Sun XW, Ellerbrock R, Lungu O, et al. Human papillomavirus infection in human immunodeficiency virus-seropositive women. Obstet Gynecol. 1995;85:680-686.
9. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000;92:1823-1830.
10. Murphy EL, Collier AC, Kalish LA, et al; Viral Activation Transfusion Study Investigators. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001;135:17-26.
11. Minkoff H, Ahdieh L, Massad LS, et al. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS. 2001;15:2157-2164.
12. Schuman P, Ohmit SE, Klein RS, et al; HIV Epidemiology Research Study (HERS) Group. Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis. 2003;188:128-136.
13. Solomon D, Davey D, Kurman R, et al; Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114-2119.
14. Cohen J, Cohen P. Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences. Oxford, UK: Lawrence Erlbaum; 1975.